A Novel Therapy System for the Treatment of Occult Prostate Cancer
Abstract
The goal of this research was to investigate efficacy and mechanisms of H5BVIFN-beta, a novel immunotherapeutic agent, against prostate cancer in animal models. The objective in year 3 was to investigate mechanisms by which H5BVIFN-beta inhibits tumor growth. We found that the therapeutic effects of H5BVIFN-beta were significantly reduced in macrophage-compromised mice and in mice deficient in inducible nitric oxide synthase. We found that intratumoral injection of H5BVIFN-beta, reduced microvessel density and downregulated expression of several angiogenic molecules, including transforming growth factor-beta1, vascular endothelial cell growth factor, and platelet-derived growth factor. Expression of antiapoptotic molecule endothelin-1 was also downregulated. Our data suggest that H5BVIFN-beta therapy suppressed tumor growth by downregulating expression of angiogenic molecules and, hence, tumor angiogenesis. This therapy should be beneficial to patient with localized prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2007
- Accession Number
- ADA469669
Entities
People
- Zhongyun Dong
Organizations
- University of Cincinnati